Abu Dhabi, UAE, 21 October 2026: Mubadala Bio’s IDS and GSK today announced a strategic alliance partnership to support the UAE’s healthcare priorities and ambitions to strengthen healthcare resilience and develop a world-class life sciences ecosystem.
The agreement was signed by Khalid Alkaf, General Manager – Pharma Logistics, Mubadala Bio, and Boyd Chongphaisal, Vice President & General Manager, GSK Gulf, and witnessed by Hamad Almarzooqi, Group Deputy Chief Executive Officer, Mubadala Bio, and Mohamed El Dababy, President, International Central Region, GSK, at the Abu Dhabi Future Health Summit.
Under the partnership, IDS will manage the sales, marketing, distribution and promotion of GSK’s General Medicines portfolio in the UAE, comprising more than 20 medicines. The collaboration combines IDS’s deep local market expertise and capabilities with GSK’s global scientific leadership and healthcare portfolio, supporting the development of local pharmaceutical capabilities and creating long term value for patients and healthcare providers in the UAE.
The partnership brings together complementary strengths and expertise, demonstrating the value of collaboration between global healthcare leaders and national champions in supporting better health outcomes for the UAE and beyond.
About Mubadala Bio
Mubadala Bio is a life sciences company dedicated to pursuing better health outcomes for the UAE and beyond. As a catalyst for progress and innovation, we are accelerating the growth of the life sciences ecosystem by enhancing drug security and expanding access to affordable, essential treatments.
Operating through two core verticals, Integrated Biopharma and Pharma Logistics, we are advancing local pharmaceutical manufacturing while ensuring timely access to critical and lifesaving medications. With a growing footprint across the UAE, Asia, Africa, and Europe, we are driving impact both locally and globally.
Our portfolio focuses on key therapy areas that address some of the world’s most pressing health needs, supporting the full continuum of care, from prevention and diagnosis to treatment, ongoing support, and complementary medicine. Headquartered in Abu Dhabi and wholly owned by Mubadala Investment Company, we are fostering innovation, cultivating local talent, and helping build a knowledge-based economy – delivering better health, closer for all.
Learn more at www.mubadalabio.ae
Discover more from DubaiGlobalNews
Subscribe to get the latest posts sent to your email.